💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Yttrium Chloride Y-90

CHEMBL5315051 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
196.3 g/mol
LogP
—
Phase
4

Yttrium chloride Y-90 is a radioactive salt containing yttrium-90, a pure beta-emitting radioisotope with a 2.7-day half-life used as a source of radioactive yttrium for labeling antibodies and other targeting molecules for cancer therapy. It is the building block for radioimmunoconjugates such as Y-90 ibritumomab tiuxetan used in non-Hodgkin lymphoma treatment. The energetic beta radiation (2.28 MeV) from Y-90 produces a crossfire effect that kills surrounding tumor cells.

น้ำหนักโมเลกุล

196.2600 g/mol

TPSA

0.00 Ų

ด้านการรักษา

Lymphoma Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

SMILES

Cl[90Y](Cl)Cl

InChI

InChI=1S/3ClH.Y/h3*1H;/q;;;+3/p-3/i;;;1+1

Molecular Formula

Cl3Y

HBD / HBA

- / -

พันธะที่หมุนได้

0

อะตอมหนัก

4

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

Yttrium chloride Y-90 is a radioactive salt containing yttrium-90, a pure beta-emitting radioisotope with a 2.7-day half-life used as a source of radioactive yttrium for labeling antibodies and other targeting molecules for cancer therapy. It is the building block for radioimmunoconjugates such as Y-90 ibritumomab tiuxetan used in non-Hodgkin lymphoma treatment. The energetic beta radiation (2.28 MeV) from Y-90 produces a crossfire effect that kills surrounding tumor cells.

Yes, Yttrium Chloride Y-90 is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5315051. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 71586740. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.